We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. iRadimed (IRMD - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
iRadimed is one of 1161 companies in the Medical group. The Medical group currently sits at #11 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. iRadimed is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for IRMD's full-year earnings has moved 16.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that IRMD has returned about 0.3% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 10.7% on average. As we can see, iRadimed is performing better than its sector in the calendar year.
Another stock in the Medical sector, Lantheus Holdings (LNTH - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 79.2%.
The consensus estimate for Lantheus Holdings' current year EPS has increased 122.4% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, iRadimed belongs to the Medical - Instruments industry, which includes 102 individual stocks and currently sits at #189 in the Zacks Industry Rank. This group has lost an average of 18% so far this year, so IRMD is performing better in this area.
In contrast, Lantheus Holdings falls under the Medical - Products industry. Currently, this industry has 91 stocks and is ranked #163. Since the beginning of the year, the industry has moved -9.1%.
Going forward, investors interested in Medical stocks should continue to pay close attention to iRadimed and Lantheus Holdings as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. iRadimed (IRMD - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
iRadimed is one of 1161 companies in the Medical group. The Medical group currently sits at #11 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. iRadimed is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for IRMD's full-year earnings has moved 16.2% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that IRMD has returned about 0.3% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 10.7% on average. As we can see, iRadimed is performing better than its sector in the calendar year.
Another stock in the Medical sector, Lantheus Holdings (LNTH - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 79.2%.
The consensus estimate for Lantheus Holdings' current year EPS has increased 122.4% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Looking more specifically, iRadimed belongs to the Medical - Instruments industry, which includes 102 individual stocks and currently sits at #189 in the Zacks Industry Rank. This group has lost an average of 18% so far this year, so IRMD is performing better in this area.
In contrast, Lantheus Holdings falls under the Medical - Products industry. Currently, this industry has 91 stocks and is ranked #163. Since the beginning of the year, the industry has moved -9.1%.
Going forward, investors interested in Medical stocks should continue to pay close attention to iRadimed and Lantheus Holdings as they could maintain their solid performance.